Vericel, developer of MACI® autologous cultured chondrocytes for cartilage repair, priced its underwritten public offering of 5MM shares of common stock at $13/share.
BONESUPPORT entered into an agreement with Collagen Matrix on U.S. sales of bone graft substitute products through its own U.S. distribution network, beginning in 4Q18.